SIREN : 434741732
HOLDING PHARMASUD IMMO is a French company founded 25 years ago, specialized in the sector Activités des sièges sociaux. Based in NARBONNE (11100), this company of category PME shows in 2019 a revenue of 5.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | N/C | N/C | 5 199 164 € | 5 014 500 € | 5 058 390 € | 5 376 891 € |
| Net income | 12 098 € | 517 080 € | -25 694 € | -17 772 € | -15 283 € | 195 177 € | 146 068 € | 85 569 € | 117 788 € |
| EBITDA | -6 509 € | -27 736 € | -14 107 € | -5 053 € | -5 788 € | 285 703 € | 227 219 € | 136 705 € | 183 752 € |
| Net margin | N/C | N/C | N/C | N/C | N/C | 3.8% | 2.9% | 1.7% | 2.2% |
In 2024, HOLDING PHARMASUD IMMO generates positive net income of 12 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 118 k€ -> 12 k€.
-6 509 €
-6 510 €
12 098 €
The debt ratio (= Financial debt / Equity x 100) stands at 2%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 96%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 3.6 years of cash flow to repay all financial debt. This ratio remains within usual banking standards.
2.46%
96.458%
3.614
In 2024, the debt ratio of HOLDING PHARMASUD IMMO (2.46) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2024, the financial autonomy of HOLDING PHARMASUD IMMO (96.5%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of HOLDING PHARMASUD IMMO (3.61) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 4996.68. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
4996.684
0.0
In 2024, the liquidity ratio of HOLDING PHARMASUD IMMO (4996.68) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of HOLDING PHARMASUD IMMO (0.0x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 55 days. Excellent situation: suppliers finance 55 days of the operating cycle (retail model).
0 €
0 j
55 j
0 j
Based on 103 transactions of similar company sales in 2024, the value of HOLDING PHARMASUD IMMO is estimated at 115 026 € (range 39 495€ - 309 731€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 103 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare HOLDING PHARMASUD IMMO with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sièges sociaux
The revenue of HOLDING PHARMASUD IMMO in 2019 is 5.2 M€.
Yes, HOLDING PHARMASUD IMMO generated a net profit of 12 k€ in 2024.
The headquarters of HOLDING PHARMASUD IMMO is located in NARBONNE (11100), in the department Aude.
The tax return of HOLDING PHARMASUD IMMO is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
HOLDING PHARMASUD IMMO operates in the sector Activités des sièges sociaux (NAF code 70.10Z). See the 'Sector positioning' section above to compare the company with its competitors.